Dendrimers possess discrete highly compact nanostructures constituted of successive branched layers. Soon after the inception of dendrimers, recognition of their tunable structures and biologically favorable properties provoked a great enthusiasm in delving deeply into the utility of dendrimers for biomedical and pharmaceutical applications. One of the most important nanotechnology applications is the development of nanomedicines for targeted cancer therapies.
Introduction
Dendrimers possess discrete highly compact nanostructures constituted of successive branched layers, which are commonly referred to as generations. 1, 2 Accompanying dendrimer generation increase, the number of branches and surface groups increases exponentially along with a stepwise increase in size. Soon after the inception of dendrimers, recognition of their tunable structures and biologically favorable properties provoked a great enthusiasm in delving deeply into the utility of dendrimers for biomedical and pharmaceutical applications. 3, 4 Dendrimers offer a high degree of flexibility in drug loading. Drugs can be either covalently conjugated to the dendrimer surface [5] [6] [7] [8] [9] [10] or physically encapsulated into the inner core. [11] [12] [13] Gene plasmids and nucleic acids can be complexed with dendrimers through electrostatic interaction. [14] [15] [16] [17] [18] [19] [20] [21] Burgeoning evidence shows that dendrimers empower development of effective There is a widespread interest in diverse topics ranging from synthesis and functionalization of dendrimers, design principles and considerations for the utility of dendrimer features, to dendrimer-based drug delivery systems for treatment of various diseases. [22] [23] [24] One of the most important nanotechnology applications is the development of nanomedicines for targeted cancer therapies. Different from conventional chemotherapy acting on rapidly dividing 4 normal and cancerous cells, targeted therapies interfere with specific molecular targets that are involved in cancer growth, progression, and spread. Tremendous success in targeted therapies has been achieved with the use of dendrimer-based nanomedicines. Targeted therapies have been grouped to different categories including hormone therapies, signal transduction inhibitors, gene therapy, apoptosis inducer, angiogenesis inhibitor, immunotherapies, and toxin delivery molecules. This article provides a concise review on latest advances in the utility of dendrimers in immunotherapies and hormone therapies.
Dendrimer nanomedicine design considerations: critical nanoscale design parameters (CNDPs)
Critical nanoscale design parameters (CNDPs), namely size, shape, surface chemistry, flexibility/rigidity, elemental composition, and architecture, have been applied to establish a nanoperiodic framework to understand nanoparticle structure control and atom-like combining properties of dendrimers. 2, 25 It is gaining increasing recognition that pharmacokinetics, pharmacodynamics, and toxicokinetics of nanomedicines in preclinical and clinical are also influenced by the CNDPs mentioned above. Uniquely, dendrimers offer defined nanostructures that can be engineered through any one of the six CNDPs ( Figure 1 ). Therefore, CNDP-directed design strategies can be implemented to develop dendrimer-based nanomedicines and offer a powerful tool for elucidation of structure-property-function relationships and optimization of the nanomedicines in the context of intended clinical applications ( Figure 1 ). 2 It is worth noting that clearance pathway of PAMAM dendrimers shows clear size (or generation)-and charge-dependence. 2, 26 PAMAM dendrimers of generation 5 or lower can be sufficiently eliminated via glomerular filtration in the pathway of renal excretion. However, 5 when size of dendrimers is close to the filtration size threshold, charge plays a significant role.
The highly negatively charged glomerular basement membrane makes it more difficult for anionic dendrimers to filtrate. As dendrimers become larger in size, their elimination relies on hepatic clearance. Dendrimer surface functionalization often leads to size increase and charge changes. Such design parameters will help predict in vivo biodistribution and clearance patterns of dendrimer nanomedicine and create more effective delivery systems.
Dendrimer-ligand conjugates for tumor cell targeting
Immunotherapies may harness the immune system to attack cancer cells with the aid of dendrimers. One strategy is to prepare immunodendrimers by surface functionalizing dendrimers with monoclonal antibodies (mAbs) that bind to the surface of cancer cells. The multivalency and hydrophobic inner core of dendrimers can then be utilized to deliver toxic molecules through covalent conjugation and encapsulation, respectively, to kill cancer cells precisely with guidance of the conjugated mAbs.
Over 70% of ovarian adenocarcinoma overly express mesothelin, a glycosyl-phosphatidyl inositol (GPI)-linked membrane protein, which can be recognized by monoclonal antibody K1 (mAbK1). Immunodendrimers were made towards ovarian cancer treatment by conjugating mAbK1 to half-generation poly (propylene imine) (PPI) dendrimers ( Figure 2 ). Paclitaxel (PTX) was encapsulated into the hydrophobic nanodomains of PPI dendrimers. Nearly 30% of the drug was entrapped in dendrimers at a drug to dendrimer ratio of 4:1. The resulting mAbK1-PPI-PTX was tested in an ovarian cancer model, and it was found to reduce tumor volume and extend animal survival more significantly through enhanced drug uptake in the tumor. In most cases, cancer cells express much higher levels of receptors on the cell surface, such as folate receptor, EGFR. In addition to mAbs, ligands that bind to those receptors can be conjugated to the dendrimer to make targeted dendrimers. It has been widely accepted that multivalent conjugation of folic acid to the dendrimers makes the conjugates have high avidity to folate binding protein. In one of our latest publications, we reported functionalization of dendrimers with EGF peptide ligands for EGFR-mediated gene delivery. 17 In this particular system, the dendrimer surface was uniformly coated with triglycine (GGG) spacer for improving cytocompatibility while maintaining positive charges for complexation with nucleic acids ( Figure 3 ). Quantum dots were conjugated to the dendrimer via a polyethylene glycol (PEG) Yang's team developed a delivery platform by hybridizing immune cell and dendrimers via highly efficient highly selective bioorthogonal reaction on the cell surface ( Figure 7 ). 39 The resulting hybrids remained good viability and motility, indicating the mildness of the chemistry and noninvasiveness to the cellular vehicle. This hybrid system takes advantage of multivalency of PAMAM dendrimers for delivery of compounds of interest such as drugs and imaging agents.
9
This approach provides a new way to utilize dendrimers and immune cells and make it possible to develop personalized immunotherapy.
Dendrimer-based hormone therapy
Hormone therapies exert therapeutic effectiveness by preventing production of hormones or impeding hormone activities. 40 Figure 8 ). 43 The high selectivity of FSH33-dendrimer conjugates was confirmed.
Furthermore, the conjugates displayed receptor antagonistic effect by downregulating surviving, an anti-apoptotic protein.
Conclusions and outlook
High-quality dendrimer products in high quantities have been made available for fundamental research and translational studies owing to commercialization of PAMAM dendrimers by several companies such as Dendritech (Midland, Michigan) and NanoSynthons (Mt. Pleasant, Michigan). The commercially available dendrimers serve as a reliable source of building blocks for development of dendrimer nanomedicine products on a large scale.
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